Optiscan has been featured in Australian Manufacturing regarding the successful completion of the beta phase for its cloud-based telepathology platform.

The article highlights the potential of the platform in enabling pathology expertise to be delivered to remote areas, to deliver high-quality patient care.

“This achievement makes the platform a potential game changer for telehealth consultations for patients who live outside of capital city areas. In the past, regional, rural, and remote health facilities have lacked the dedicated pathology expertise, limiting collaboration and immediate decision-making between clinicians and pathologists,” Dr Camile Farah, Optiscan CEO.

Read the full article here.